Premium
Serological hepatitis B virus (HBV) activity in patients with HBV infection and B‐cell non‐Hodgkin’s lymphoma
Author(s) -
Zhou Xiang,
Wuchter Patrick,
Egerer Gerlinde,
Kriegsmann Mark,
Kommoss Felix K. F.,
WitzensHarig Mathias,
Kriegsmann Katharina
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13388
Subject(s) - hepatitis b virus , medicine , lymphoma , serology , hbsag , non hodgkin's lymphoma , hepatitis b , diffuse large b cell lymphoma , gastroenterology , b cell , immunology , virus , antibody
Background Previous epidemiological studies suggest an association between hepatitis B virus (HBV) infection and B‐cell non‐Hodgkin lymphoma (B‐NHL). The aim of our study was to evaluate clinical characteristics and serological indicators of HBV activity in patients who were diagnosed with both HBV infection and indolent or aggressive B‐NHL. Methods Seventy‐two patients with current or resolved HBV infection and B‐NHL were identified between 2000 and 2017 at our institution. Results Forty‐five (63%) and 27 (37%) patients were identified with aggressive and indolent B‐NHL, respectively. In indolent B‐NHL, the proportion of HBsAg‐positive patients was significantly higher compared with aggressive B‐NHL (59% vs 38%, P = .03). HBV‐DNA levels were significantly higher in patients with indolent compared to aggressive B‐NHL ( P = .01). In the subgroup analyzes of follicular lymphoma (FL) and diffuse large B‐cell lymphoma (DLBCL), the rate of HBsAg positivity in FL is significantly higher than that in DLBCL (83% vs 44%, P = .04), and HBV‐DNA levels were significantly higher in FL compared with DLBCL ( P = .007). Conclusion Our results suggest that serological HBV activity is higher in patients with both HBV infection and indolent B‐NHL compared to those with aggressive B‐NHL.